• Mutations in PRKCD cause a syndrome characterized by chronic benign lymphadenopathy, positive autoantibodies, and NK dysfunction.
Introduction
Protein kinase C (EC 2.7.11.13), also known as PKC, is a family of serine/threonine kinases that play a key role in the regulation of various cellular processes, including cell proliferation, apoptosis, and differentiation. 1, 2 In humans, at least 11 different PKC polypeptides have been identified. On the basis of their requirements, the PKC family is divided in 3 subfamilies as follows: the conventional PKCs (cPKC; a, bI, bII, and g), the novel PKCs (nPKC; d, e, h, and u) and the atypical PKCs (aPKC; z and l/i). nPKCs require diacylglycerol (DAG) but not calcium (Ca 21 ) for activation. Specifically, PKCd (OMIM 176977, also known as PKCD, PRKCD) is activated via DAG produced by receptor-mediated hydrolysis of membrane inositol phospholipids as well as by phorbol ester. Numerous studies in humans and mice have shown that PKCd has important roles in B-cell signaling and autoimmunity, as well as regulation of growth, apoptosis, and differentiation of a variety of cell types. [1] [2] [3] [4] [5] [6] Interestingly, mice homozygous for a null allele of the gene that encodes PKCd, PRKCD (National Center for Biotechnology Information gene ID 5580), exhibit some of the signs of the autoimmune lymphoproliferative syndrome (ALPS; OMIM 601859), 7 including autoimmunity, neutropenia, and increased B-cell numbers and proliferation, 3 making PKCd an appealing candidate gene for humans with ALPS-like disease.
In this study we identified a homozygous PKCd loss-of function mutation in a patient with autoimmunity, lymphoproliferation, and chronic Epstein-Barr virus (EBV) infection. Our results establish PKCd as a key protein regulating B-cell proliferation and tolerance as well as NK function in humans. The online version of this article contains a data supplement.
Materials and methods
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. from healthy control patients was obtained under approved protocols of these centers.
Cell lines and culture
EBV-transformed B-cell lines derived from patients and normal donors were maintained in RPMI 1640 with 20% fetal calf serum (Gibco), 2mM L-glutamine, penicillin 100 U/mL, and 100 mg/mL streptomycin (Gibco) at 37°C in a humidified 5% CO 2 incubator. Peripheral blood mononuclear cells (PBMCs) were isolated by the use of Ficoll separation (Lonza). Human B cells were purified by negative selection by use of the StemSep Human B-cell Enrichment kit according to the manufacturer's instructions (StemCell Technologies). PBMCs were cultured in 10% complete media as stated previously.
DNA sequencing and bioinformatics methods
The patient's genomic DNA was submitted to Otogenetics for whole exome capture (Agilent V4; 51 Mbp) and next-generation sequencing on the Illumina HiSeq2000. Sanger DNA sequencing was performed with the use of purified polymerase chain reaction (PCR) products amplified by PRKCD exon2specific primers and GoTaq Hot Start Polymerase (Promega); PCR products were directly sequenced with BigDye Terminators (version 1.1) and analyzed on a 3130xL Genetic Analyzer (Applied Biosystems).
The DNAnexus interface was used to align the Illumina reads to the hg19 human reference genome and perform SNP and INDEL discovery and genotyping. To prioritize the 37 950 variant calls, we implemented the ANNOVAR functional annotation package 8 and filtered the output on the basis of gene/amino acid annotation, functional prediction scores (SIFT, PolyPhen, LRT, MutationTaster), conservation scores (PhyloP and GERP11), and allele frequencies per the National Center for Biotechnology Information dbSNP database (build 132), The 1000 Genomes Project (2011 May release), and the National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project (ESP5400). Only nonsynonymous novel variants or variants with population frequencies ,1% were considered further. Variants in segmental duplication regions also were excluded. Exomic variants were finally prioritized on the basis of clinical correlation.
Immunohistopathology
Anti-PKCd stains were performed on FFPE samples with a reactive tonsil as positive control. Sections were deparaffinized in xylene, rehydrated in graded-alcohol, placed in a hot 13 low pH antigen retrieval solution (Dako, S1699), and microwaved for 6 minutes. Sections were allowed to cool down for 5 minutes, blocked with Tris-goat immunoglobulin (Ig) for 15 minutes, and incubated for 60 minutes at room temperature with anti-PKCd polyclonal rabbit antibody (A7034; Sigma-Aldrich) at 1:200 dilution. Detection was performed on a Ventana BenchMark using a Ventana iView DAB detection kit (AZ, 760-091). The other immunohistochemical (IHC) stains included CD20, CD3, CD5, BCL-6, Mum-1, CD21, MIB-1, k, l, IgM, IgD, IgG, IgA, TdT, and EBV-encoded RNA (EBER). These were performed as previously published. 9 Images were taken using an Olympus Bx41 microscope, objective UPlanFI 103/030 and 203/0.50 '/0.17, with an adaptor U-TV0.5xC using a digital camera Q-imaging Micropublisher 5.0 RTV. The images were captured using "Q-Capture Version 3.1" and imported into Adobe Photoshop 7.0
Evaluation of cell proliferation
PBMCs, either freshly isolated or thawed from liquid nitrogen2stored samples, were incubated with CellTrace CFSE Cell Proliferation Kit (1 mM; Invitrogen). After 5 minutes, 10 volumes of RPMI/10% fetal bovine serum (FBS) were added, and the cells were centrifuged and washed twice more with RPMI/10% FBS. A total of 2 3 10 5 cells were seeded into 48-well plates, stimulated with CD3/CD28 (Dynabeads T-cell activator from Invitrogen), or phytohemagglutinin (1 m/mL; Sigma-Aldrich) as indicated in the figures, and cultured for 3-4 days. Carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled cells were stained with APC-CD25 (BD Biosciences) or IgG control for 30 minutes at 4°C (dark). Cells were washed with PBS twice, and 10 000 live cells were analyzed by flow cytometry (Becton Dickinson FACSCanto II). For B-cell proliferation, 1 3 10 5 CFSE-labeled B cells were stimulated with F(ab9) 2 anti-IgM (10 mg/mL; Jackson Laboratory), IL-4 (50 ng/mL; Cell signaling), and CD40 ligand (10 mg/mL; Cell signaling) for 5-6 days, and 10 000 live cells were analyzed by flow cytometry.
Cytokine measurement
Human B cells were purified by negative selection with the StemSep Human B-cell Enrichment kit according to the manufacturer's instructions. A total of 1 3 10 5 B cells were stimulated with F(ab9) 2 anti-IgM (10 mg/mL), IL-4 (50 ng/mL), and CD40 ligand (10 mg/mL) for 48 hours and cell-free supernatants were harvested. Interleukin (IL)-6 and IL-10 cytokines were measured simultaneously with Fluorokine MAP Human Base Kit A (R&D Systems) using the Luminex 200 System (Luminex Corporation). 
Gene expression
Total RNA was isolated from PBMCs or EBV-transformed B-cell lines with the RNeasy plus mini Kit (QIAGEN). One microgram of total cellular RNA was reverse transcribed by use of the iScript cDNA synthesis kit (Bio Lad). Gene expression was analyzed by real-time PCR using a StepOne Plus real time PCR (Applied Biosystems) and Taqman probes (Applied Biosystems) performed according to manufacturer's instructions. All reactions were performed in triplicate for 40 cycles. GAPDH was used as the endogenous control, and gene expression of PRKCD was quantitatively measured relative to 2 different normal donors. The relative quantitation of PRKCD expression was calculated with the comparative Ct method. For each sample, the threshold cycle (Ct) was determined, and the relative fold expression was calculated as follows: DCt 5 Ct of PRKCD 2 Ct of GAPDH. DDCt 5 DCt of the normal sample 2 DCt of the patient sample. The relative fold expression was calculated using the equation 2
DDCt .
Transduction using lentivirus
PRKCD coding sequence was cloned into pLVX-IRES-ZsGreen (Clontech). The packaging mix (Clontech) and the pLVX-IRES-ZsGreen control vector or pLVX-IRES-ZsGreen-PRKCD were cotransfected into Lenti-X-293 cells (4 3 10 6 cells) with X-fect transfection reagent (Clontech) according to the manufacturer's instruction. After 48 hours' incubation, supernatant was collected and concentrated with Lenti-X concentrator (Clontech). Concentrated virus was resuspended with RPMI media and transduced into the patient's EBV B-cell line. To improve infection efficiency, Polybrene (8 mg/mL) was added into media followed by centrifugation at 1500g for 1 hour. After 24 hours, the media was changed to virus-free complete RPMI media, and the cells were incubated for an additional 72 hours.
siRNA transfection
Small interfering RNA (siRNA)-universal negative control and siRNA-PRKCD were purchased from Sigma-Aldrich. B cells (325 3 10 6 cells) and PBMCs (1 3 10 6 cells) were transfected with 300 nM siRNA by the use of Amaxa electrophoration according to manufacturer's instructions. The next day, transfected cells were washed with fresh RPMI/10% FBS, stained with CellTrace CFSE, and stimulated as described above. Using the Lonza transfection kit, we found that transfection efficiency was 25% in the B cells and 70% in the T cells within the PBMCs as determined by the pmaxGFP.
Statistical analysis
The data are presented as the means 6 SE, and statistical analyses were performed with unpaired Student t test. The differences were considered significant when P , .05. The n values represent the number of experiments from multiple preparations.
Results

Clinical and laboratory findings
The patient is a Hispanic male born at term in 2005 to parents without known consanguinity; however, the families of both parents have been inhabitants of the same small town in northern Mexico for many generations ( Figure 1A ). His clinical history included recurrent otitis with bilateral perforated tympanic membranes and sinusitis that starting during in early childhood. He had persistent generalized lymphadenopathy and hepatosplenomegaly ( Figure 1B, left) , accompanied by intermittent fevers starting at 3 years of age. Hepatosplenomegaly became very prominent by 5 years of age and marked mediastinal lymphadenopathy produced a superior vena cava syndrome manifested by markedly dilated chest veins. He had an intermittent facial rash in a butterfly distribution and confluent erythematous macules over the trunk and extremities but no other evidence for vasculitis or glomerulopathy. The patient had several autoantibodies at high titers, which are listed in Table 1 . These autoantibodies (extractable nuclear antigens [ENAs]) had not lead to disease-specific manifestations other than a period of lupus-like rash. Shortly after this, he was started on immunomodulatory treatment.
Laboratory evaluation at 5 years revealed a slight leukocytosis, normochromic normocytic anemia, and borderline thrombocytopenia that were presumed to be secondary to splenic sequestration as there was no evidence for an autoimmune cytopenia. Significantly increased sedimentation rate and C-reactive protein, aspartate aminotransferase and alanine aminotransferase elevation, and hypergammaglobulinemia also were noted at this time (Table 1) . Flow cytometry revealed B-cell lymphocytosis (30% of lymphocytes) with the majority of B cells expressing CD5, whereas class switched B-cell memory subsets were diminished ( Table 1) .
The patient had previous evidence for seroconversion to EBV, although he had persistently detectable EBV copy numbers between 2000 and 8000 genomes/mL. NK cells were slightly decreased, but his NK-cell cytolytic activity was very diminished as compared with normal control patients (supplemental Figure 1 ; see the Blood Web site); NKT cells were present in normal numbers. Although the patient did not have a significant and persistent increase in a-b T-cell receptor double-negative T cells, molecular screening for ALPS and ALPS-like related genes (FAS, FASL, CASP8, CASP10, NRAS, or KRAS) was undertaken and revealed no mutations. In addition, no mutations were detected in the Xlinked lymphoproliferative disease genes SH2D1A and XIAP.
In an attempt to reduce his lymphadenopathy, the patient was treated with corticosteroids and rapamycin, which led to a remarkable and rapid reduction in the size of his lymph nodes and resolution of hepatosplenomegaly ( Figure 1B, right) , as well as the transaminitis and elevated inflammatory markers. BLOOD, 18 APRIL 2013 x VOLUME 121, NUMBER 16 PKCd DEFICIENCY CAUSES ALPS-LIKE DISEASE 3119
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PRKCD mutation and gene expression
To identify the underlying genetic defect in the patient, we performed whole-exome sequencing and identified a deleterious PRKCD c.1840C.T, p.R614W homozygous mutation. This result was confirmed by Sanger sequencing ( Figure 3A) . Both parents and all 3 siblings are heterozygous carriers, and they are healthy without any clinical evidence or history of lymphoproliferation and/or autoimmunity ( Figure 3A) . The p.R614W mutation is located in the nuclear localization sequence, which has been shown to be important for the nuclear import of PKCd, a process required for apoptosis. 11 Western blot analysis revealed low levels of PKCd protein expression in the patient's PBMCs, B cells, and EBVtransformed B cells, although the mRNA expression level was For personal use only. on May 6, 2017. by guest www.bloodjournal.org From comparable or greater than that of normal cells ( Figure 3B-C) . Western blots also demonstrated normal expression of the other PKC isoforms (PKCa, b, e) in PBMCs and in EBV-transformed B cells (data not shown), indicating that PKCd protein expression is specifically reduced in the patient. We also confirmed absence of PKCd expression in the patient's lymph node by immunohistochemistry ( Figure 2K ). We also tested PKCd protein expression in heterozygous family members, and the PKCd expression was similar to heath control (data not shown).
PKCd deficiency induces increased B-cell proliferation
Recently, the generation of PKCd 2/2 mice has revealed a striking functional role for this protein in B-cell proliferation and maintenance of tolerance. 3 PKCd 2/2 mice exhibit B-lineage2specific cell expansion with increased number of naïve and activated follicular mature B cells and an increased number of germinal centers within the spleen and peripheral lymph nodes. 3 Interestingly, the patient's phenotype, including enlarged spleen and lymph nodes, and an expanded peripheral B lymphocyte population involving predominantly naïve cells, was similar to those of PKCd 2/2 mice. To test whether the patient's B cells were hyperproliferative, we measured the proliferative potential of B cells from PBMCs by using CFSE staining. Stimulation of purified B cells with either F (ab9) 2 anti-IgM alone or in combination with IL-4 and CD40 ligand revealed that the proliferative response of the patient's B cells was significantly greater than that of B cells from a normal control ( Figure 4A ). EBV-transformed B cell lines from the patient also grew at a faster rate than control lines ( Figure 4B ). In contrast, T cells from the patient did not display an increased rate of proliferation compared with healthy controls ( Figure 4C ).
The hyperproliferative B-cell phenotype seen in the PKCd 2/2 mice was suggested to be secondary to an augmented B-cell secretion of IL-6. 3 Evaluation of IL-6 secretion by the patient's B cells after activation did not show statistically significant differences from the controls ( Figure 4D ). However, there was a striking elevation in IL-10 secretion by the patient's B cells compared with healthy controls ( Figure 4E ).
To demonstrate that the PKCd deficiency was responsible for the B-cell hyperproliferative phenotype, we used siRNA to knock down PRKCD in B cells from healthy volunteers. Despite the low B-cell transfection efficiency (;25%), an increase in B-cell proliferation was evident in siRNA-PKCd transfected cells (Figure 5A-B) . In contrast, the proliferative properties of siRNA-PKCd primary T cells appeared normal ( Figure 5B ). Taken together, these experiments demonstrated that PKCd deficiency in humans causes abnormal B-cell proliferation but does not appear to affect T cell proliferation.
PMA-induced apoptosis is defective in PKCd deficiency
Phorbol esters, natural compounds that potently activate the classical and novel PKCs, trigger cell survival responses or apoptosis depending on the cell type and the relative expression of individual PKC isozymes. 4, 12 Numerous studies have shown that PKCd is involved in proapoptic signaling upon phorbol ester stimulation and after DNA damage. 13 Therefore, we tested PMAinduced cell death in the patient's cells (EBV-transformed B cells and PBMCs). Although treatment with PMA induced 60% and 50% cell death in EBV-transformed B cells (Figure 6A-B) and PBMCs from normal control patients ( Figure 6C) , respectively, the patient's cells were completely resistant to BLOOD, 18 APRIL 2013 x VOLUME 121, NUMBER 16 PKCd DEFICIENCY CAUSES ALPS-LIKE DISEASE 3121
For personal use only. on May 6, 2017. by guest www.bloodjournal.org From PMA-induced cell death. However, they demonstrated normal sensitivity to alternative inducers of apoptosis, including FAS and thapsigargin ( Figure 6A -B and data not shown). It is well known that PKCd is required for caspase-3 activation and induction of apoptosis after PMA overstimulation. To test whether deficiency of PKCd expression interferes with caspase-3 activity and apoptosis, we measured capspase-3 activity with flow cytometry. As seen in Figure 6D , the patient's EBVtransformed B cells failed to activate caspase-3 whereas the caspase-3 activity of the normal cells was increased by PMA. PBMCs also showed a similar defect in PMA-induced caspase-3 activation (data not shown).
To demonstrate that the lack of PKCd expression resulted in the defective PMA-induced cell death, we overexpressed wild-type PKCd in the patient EBV B cells by the use of a lentiviral vector ( Figure 6E ). The overexpression of PKCd in patient's EBVtransformed B cells partially re-established the capacity of PMA to induce cell death ( Figure 6F ).
NK function studies
Although we are not aware of NK dysfunction in the PKCd 2/2 mouse, given our patient's chronic persistent EBV low-grade viremia, we explored this possibility. Using 51 Cr-labeled K562 target cells, we found that the patient's PBMCs exhibited markedly reduced NK activity, notably at greater effector/target ratios (supplemental Figure 2 ). In addition, in an enzyme-linked immunospot assay in which K562 target cells were used, we found that the patient's PBMCs exhibited a reduced frequency of interferon-g2producing cells: 0.03% (300 of 1 3 10 6 PBMCs) in the patient vs 0.12% to 0.35% in 2 control subjects (data not shown).
Discussion
We report here the first human disorder caused by PKCd deficiency. Similar to the PKCd 2/2 mouse, our patient presented with extensive lymphadenopathy and breakdown of B-cell tolerance, with autoantibody production and lupus-like skin disease. 3 The impressive lymphocyte accumulation could be explained by the excessive proliferation of the patient's B cells demonstrated ex vivo in the presence of substimuli such as anti-IgM treatment, which normally does not induce B-cell division. This finding translated histopathologically into lymph nodes with numerous follicles but lacking adequate germinal center and mantle separation, with fewer than normal BCL6-positive B cells. Peripheral blood immunophenotyping was also abnormal, with diminished memory B cells and increased numbers of CD5 1 B cells. Interestingly, although in mice the B-cell hyperproliferative phenotype could be ascribed to an increased secretion of IL-6, we could not document the same in our patient. In contrast, we noticed a striking oversecretion of IL-10 by the patient's cultured B cells. Because IL-10 is a B-cell trophic factor, this could explain in part the cellular phenotype. Interestingly, increased levels of IL-10 are a consistent finding in patients with ALPS, and this disorder is also associated with B-cell expansion, including increased CD5 1 B cells, decreased memory B cells, and hypergammaglobulinemia. 14, 15 In addition, it is known that PKCd itself is a negative regulator of the cell cycle. [16] [17] [18] In addition to B-cell hyperproliferation, we also documented an apoptotic defect in B cells after PMA stimulation that was not observed using other stimuli of apoptosis. The striking breakdown in B-cell tolerance seen in this patient highlights the key role of PKCd in the maintenance of human Bcell homeostasis. This confirms findings in murine models that PKCd is crucial for the adequate negative selection of B cells in the bone marrow. 6, 19 B-cell selection seems to be affected by DAGindependent Ca 21 signaling mediated by PKCd, STIM1, and RasGRP, resulting in proapoptotic Erk signaling. 19 The T-cell compartment appeared largely normal in the patient, with appropriate numbers of T-cell subsets and normal T-cell proliferation and activation in vitro. This finding is corroborated in vivo by the lack of clinical symptoms suggestive of cellular immunodeficiency. However, NK-cell function was severely impaired in our patient, as demonstrated by 3 separate assays, and serves as an explanation for the chronic, low-grade EBV infection observed in this individual. Further studies are necessary to understand how PKCd deficiency affects NK-cell function.
The patient had an excellent clinical response to immunosuppressive treatment when we used a combination of rapamycin with The next day cells were stained with CFSE (1 mM) and stimulated with F(ab9)2 specific for anti-IgM (10 mg/mL), IL-4 (50 ng/mL), and CD40 ligand (10 mg/mL) for 5 days (for B cells) or Dynabeads T cell activator CD3/CD28 for 3 days (for PBMCs). Percent cells having undergone at least one cellular division, (numbers above the lines), assessed by CFSE dilution. Gray solid peak is unstimulated cells. Data are representative of 3 independent experiments.
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For personal use only. on May 6, 2017. by guest www.bloodjournal.org From steroids that resulted in rapid reversal of the lymphadenopathy and hepatosplenomegaly. It is noteworthy that rapamycin has proven to be an effective therapeutic agent in controlling lymphoproliferation in patients with ALPS. 20 Taken together, our studies define a novel immunodeficiency presenting with lymphoproliferative disorder and NK dysfunction, and establish PKCd as a key player in the maintenance of B-cell tolerance.
